Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Udo Holtick

Showing results (21-30 of 95) with videos related to

Pageof 10
Sort By:
The Cochrane Database of Systematic Reviews|September 14, 2012
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adultsSebastian Theurich, Hans Fischmann, Alexander Shimabukuro-Vornhagen, et al.
EMBO Molecular Medicine|January 6, 2025
CAR T-cell-associated secondary malignancies challenge current pharmacovigilance conceptsPhilipp Berg, Gabriele Ruppert-Seipp, Susanne Müller, et al.
European Journal of Haematology|December 20, 2019
Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: A retrospective analysisAchim Rothe, Annika Claßen, Jonathan Carney, et al.
Haematologica|February 9, 2019
Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experienceRon Ram, Christof Scheid, Odelia Amit, et al.
European Journal of Haematology|April 15, 2024
Post-transplant-cyclophosphamide and short-term Everolimus as graft-versus-host-prophylaxis in patients with relapsed/refractory lymphoma and myeloma-Final results of the phase II OCTET-EVER trialTim Richardson, Christof Scheid, Marco Herling, et al.
Critical Reviews in Oncology/Hematology|January 22, 2015
Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults - a systematic review and meta-analysisUdo Holtick, Melanie Albrecht, Jens M Chemnitz, et al.
Transplantation|November 30, 2006
Impact of mismatching CD1a, a dimorphic antigen-presenting molecule, on graft-versus-host disease after hematopoietic stem cell transplantationEleanor M Lanning, Udo Holtick, Anne M Dickinson, et al.
Annals of Hematology|August 30, 2024
The life threat in hematopoietic allogeneic stem cell transplantation - an interview and focus group study on health care professionals' perspectivesAlinda Reimer, Merle Ley, Carolin Schepers, et al.
European Journal of Haematology|October 23, 2015
Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibodyGeothy Chakupurakal, María Alejandra García-Márquez, Alexander Shimabukuro-Vornhagen, et al.
Annals of Hematology|May 18, 2011
Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemiaJens Marcus Chemnitz, Marie von Lilienfeld-Toal, Udo Holtick, et al.
Pageof 10

Showing results (21-30 of 95) with videos related to

Sort By:
Pageof 10
The Cochrane Database of Systematic Reviews|September 14, 2012
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adultsSebastian Theurich, Hans Fischmann, Alexander Shimabukuro-Vornhagen, et al.
EMBO Molecular Medicine|January 6, 2025
CAR T-cell-associated secondary malignancies challenge current pharmacovigilance conceptsPhilipp Berg, Gabriele Ruppert-Seipp, Susanne Müller, et al.
European Journal of Haematology|December 20, 2019
Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: A retrospective analysisAchim Rothe, Annika Claßen, Jonathan Carney, et al.
Haematologica|February 9, 2019
Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experienceRon Ram, Christof Scheid, Odelia Amit, et al.
European Journal of Haematology|April 15, 2024
Post-transplant-cyclophosphamide and short-term Everolimus as graft-versus-host-prophylaxis in patients with relapsed/refractory lymphoma and myeloma-Final results of the phase II OCTET-EVER trialTim Richardson, Christof Scheid, Marco Herling, et al.
Critical Reviews in Oncology/Hematology|January 22, 2015
Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults - a systematic review and meta-analysisUdo Holtick, Melanie Albrecht, Jens M Chemnitz, et al.
Transplantation|November 30, 2006
Impact of mismatching CD1a, a dimorphic antigen-presenting molecule, on graft-versus-host disease after hematopoietic stem cell transplantationEleanor M Lanning, Udo Holtick, Anne M Dickinson, et al.
Annals of Hematology|August 30, 2024
The life threat in hematopoietic allogeneic stem cell transplantation - an interview and focus group study on health care professionals' perspectivesAlinda Reimer, Merle Ley, Carolin Schepers, et al.
European Journal of Haematology|October 23, 2015
Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibodyGeothy Chakupurakal, María Alejandra García-Márquez, Alexander Shimabukuro-Vornhagen, et al.
Annals of Hematology|May 18, 2011
Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemiaJens Marcus Chemnitz, Marie von Lilienfeld-Toal, Udo Holtick, et al.
Pageof 10